Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Stock Down 5.4 %

Evogene stock opened at $1.57 on Monday. The company’s 50-day moving average price is $1.64 and its 200-day moving average price is $3.08. Evogene has a twelve month low of $1.20 and a twelve month high of $10.40. The company has a market cap of $8.42 million, a PE ratio of -0.35 and a beta of 1.30.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC purchased a new position in Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.